• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 8

Dr Reddys Laboratories Ltd has announced that Ultravex (Halobetasol) has been launched nationwide in June. This marks the entry of the company into dermatology care, especially the Rs 100-crore topical steroid market. Halobetasol is a super-potent steroid and, hence, has a higher efficacy associated with the product. Ultravex is currently available in 10g pack and is used in the treatment of psoriasis and chronic dermatoses.

The topical steroid market is the second most prescribed category by dermatologists with nearly 2.5 crore units sold every year. With the launch of this product, the company steps into a mass specialty area which has an higher incidence of prescription due to its indication (psoriasis and chronic dermatoses), a release from the Hyderabad-based Dr Reddy's said here on Friday.

More Stories on : New Products & Services | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
TV 18 floats new division

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line